Overview
Paradox Biosciences develops next-generation small-molecule therapeutics targeting synaptic plasticity pathways for the treatment of treatment-resistant depression and PTSD.
More in Neuropharmaceuticals
Latest industry news
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Aurenar Raises $5.7M to Bring Stroke Neuromodulation to the Recovery Room
2026-08-30 · Funding
ReVision Implant Secures €4 Million to Push Visual Prosthetics Into a New Era
2026-08-29 · Funding
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Advance Neuroscience
2026-08-28 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, CA
Funding
Series A — $42M
Website
paradoxbiosciences.comListed
2026-08-31
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →